Zai lab and argenx announce approval of vyvgart hytrulo for chronic inflammatory demyelinating polyneuropathy (cidp) in china

Shanghai & cambridge, mass.--(business wire)--zai lab limited (nasdaq: zlab; hkex: 9688) and argenx (euronext & nasdaq: argx) today announced that china's national medical products administration (nmpa) approved the supplemental biologics license application (sbla) for vyvgart hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (cidp). vyvgart hytrulo is approved for ci.
ARGX Ratings Summary
ARGX Quant Ranking